Oxford BioDynamics’ portfolio of clinical smart tests based on EpiSwitch® technology aims to help people face the most challenging health decisions with confidence and tackle the rising costs of healthcare.
We are partnering with state-of-the-art CLIA-certified commercial labs to rapidly deliver clinical tests into the hands of physicians helping to inform a treatment plan tailored for their patients.
An effective prostate cancer detection test that identifies an individual’s current likelihood of prostate cancer from blood. PSE is administered alongside or following a standard PSA test to significantly boost detection performance and reduce the number of men referred for unnecessary biopsies and treatments.
This powerful test is valuable for identifying individuals requiring biopsy and those suitable for active surveillance without further testing.
Learn more about EpiSwitch PSE
A first-of-its-kind blood test to provide guidance on navigating the toughest challenges associated with use of an essential, widely-used class of cancer therapies: Immune Checkpoint Inhibitors.
Now every patient can benefit from the world’s first test to assess the probability of therapeutic success of checkpoint-inhibitor therapy with high accuracy.
Learn more about EpiSwitch CiRTReady to use powerful EpiSwitch tools + a full-stack bioinformatic tool suite with low analytical overhead.
With the power of EpiSwitch Array Kit and EpiSwitch Portal, we are able to rapidly build and deploy powerful molecular tests to address the most challenging questions in precision medicine and clinical trial stratification.
Reproducible high-resolution 3D genomics-in-a-box.
EpiSwitch Array enables rapid, sensitive mapping of the regulatory 3D whole genome.
Turnkey, full-stack analytics + genome mapping suite.
3D genomics and its biological context are key to diagnosing disease and determining health.
Expert, validated industrial delivery of 3D genomic biomarkers.
EpiSwitch analysis services utilize our proprietary validated industrial platform for 3D genomic biomarkers for pharma.
The growing pipeline includes diagnostic/prognostic tests for early-stage detection and staging of prostate cancer and colorectal cancer, diagnostic, prognostic, predictive and monitoring tests in indications such as rheumatoid arthritis (RA), amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig’s Disease or motor neuron disease), multiple sclerosis (MS), lymphoma and other cancers and, in veterinary medicine, a diagnostic/prognostic test for canine lymphoma.
Learn More about EpiSwitch Platform